m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05278
 [1]
Non-coding RNA miR-6125 YTHDF2  lncRNA       miRNA   circRNA Direct Inhibition m6A modification GSK3B GSK3B YTHDF2 : m6A sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
m6A Target Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-6125 microRNA View Details
Regulated Target YTH domain-containing family protein 2 (YTHDF2) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary hsa-miR-6125 targeted the 3'-UTR of YTHDF2 and downregulated the YTHDF2 protein, thereby increasing the stability of m6A-modified Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) mRNA.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
In-vivo Model nude mice were randomly divided into four groups and injected subcutaneously with SW480 (Vector), SW480 (miR-6125), RKO (Vector) or RKO (miR-6125) cells on the back region (5.0 × 106 cells in 100 μl PBS/mouse).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) 88 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name AMO-02 Phase 2/3 [2]
MOA Inhibitor
External Link
TTD: D0BS5E
 Compound Name Tideglusib Phase 2 [3]
Synonyms
NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 78 nM
External Link
CID: 11313622
TTD: D0UT7X
DrugBank: DB12129
 Compound Name 9-ING-41 Phase 2 [4]
Synonyms
1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44582816
TTD: D4USX5
 Compound Name LY2090314 Phase 2 [5]
Synonyms
603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt
    Click to Show/Hide
MOA Modulator
Activity IC50 = 0.9 nM
External Link
CID: 10029385
TTD: D0Z1DH
DrugBank: DB11913
 Compound Name Lithium Phase 2 [6]
Synonyms
7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415] [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414] [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3028194
TTD: D5MF8Y
 Compound Name Neu-120 Phase 1/2 [7]
Synonyms
Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0D1UQ
 Compound Name TDZD-8 Patented [8]
Synonyms
327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3 Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 690 nM
External Link
CID: 4124851
TTD: D06KNK
 Compound Name AR-A014418 Patented [9]
Synonyms
487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N& -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.07 nM
External Link
CID: 448014
TTD: D0A3MV
DrugBank: DB01950
 Compound Name PMID26161698-Compound-18 Patented [10]
MOA Inhibitor
Activity IC50 = high nM
External Link
CID: 136273305
TTD: D0F7DS
 Compound Name CHIR-99021 Patented [11]
Synonyms
CHIR99021; CHIR 99021; CT-99021; CT99021
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 30 nM
External Link
CID: 9956119
TTD: D0YK9D
 Compound Name KENPAULLONE Patented [12]
Synonyms
142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 23 nM
External Link
CID: 3820
TTD: D00PWQ
 Compound Name AZD-1080 Discontinued in Phase 1 [13]
MOA Modulator
Activity IC50 = 31 nM
External Link
CID: 135564570
TTD: D0MC0O
 Compound Name SAN-61 Terminated [14]
Synonyms
SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07YNH
 Compound Name RO-320432 Terminated [15]
Synonyms
ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 20 nM
External Link
CID: 127757
TTD: D0R5ZR
 Compound Name 8-O-(4-chlorobenzenesulfonyl)manzamine F Investigative [16]
Synonyms
CHEMBL400717
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7200 nM
External Link
CID: 23643731
TTD: D00AAN
 Compound Name N,8-diphenyl-9H-purin-6-amine Investigative [17]
Synonyms
CHEMBL1210175; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 16 nM
External Link
CID: 46894037
TTD: D00HUP
 Compound Name N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide Investigative [17]
Synonyms
CHEMBL1210476
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1220 nM
External Link
CID: 49863103
TTD: D00XUF
 Compound Name N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086639; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 94 nM
External Link
CID: 22319573
TTD: D01IPF
 Compound Name GSK-3beta inhibitor II Investigative [19]
Synonyms
GSK-3b inhibitor II
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 390 nM
External Link
CID: 6539732
TTD: D01MEP
 Compound Name 3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione Investigative [20]
Synonyms
SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 520 nM
External Link
CID: 6539451
TTD: D01OJG
 Compound Name 8-O-(4-bromobenzenesulfonyl)manzamine F Investigative [16]
Synonyms
CHEMBL414128
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 23000 nM
External Link
CID: 23643732
TTD: D01RKI
 Compound Name I-5 Investigative [21]
Synonyms
SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 76 nM
External Link
CID: 448008
TTD: D02OPH
DrugBank: DB01793
 Compound Name GSK-3beta inhibitor XI Investigative [22]
Synonyms
GSK-3b inhibitor XI
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
CID: 10020713
TTD: D02ZIY
 Compound Name Manzamine E Investigative [23]
MOA Inhibitor
External Link
CID: 6474830
TTD: D03GQF
 Compound Name N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1084681; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5008 nM
External Link
CID: 22319694
TTD: D03OED
 Compound Name N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1353 nM
External Link
CID: 10380885
TTD: D04ACJ
 Compound Name N-(6-bromo-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 198 nM
External Link
CID: 10423871
TTD: D04VBD
 Compound Name Manzamine Y Investigative [23]
Synonyms
CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10393120
TTD: D05GIC
 Compound Name IM-12 Investigative [24]
Synonyms
1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 53 nM
External Link
CID: 25209788
TTD: D05SXF
 Compound Name N-(6-phenethyl-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1084684; SCHEMBL6489338
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8525 nM
External Link
CID: 22319484
TTD: D06YMZ
 Compound Name N-(6-benzyl-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1077260; SCHEMBL6490520
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4140 nM
External Link
CID: 10266409
TTD: D07IVD
 Compound Name (2'Z,3'E)-7-Azaindirubin-3'-oxime Investigative [25]
MOA Inhibitor
External Link
CID: 44614397
TTD: D07MZD
 Compound Name N-(6-phenyl-1H-indazol-3-yl)butyramide Investigative [26]
Synonyms
CHEMBL1086174; SCHEMBL4493121
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 390 nM
External Link
CID: 10085013
TTD: D07PTD
 Compound Name Neo-kauluamine Investigative [23]
MOA Inhibitor
External Link
CID: 44448144
TTD: D09AEV
 Compound Name (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086176
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2459 nM
External Link
CID: 22319483
TTD: D09BQY
 Compound Name 8-OH-MANZAMINE A Investigative [23]
Synonyms
8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; (+)8-Hydroxymanzamine A; CHEBI:66669
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5270765
TTD: D09ITI
 Compound Name 6-deoxymanzamine X Investigative [16]
MOA Inhibitor
External Link
CID: 44445400
TTD: D09RYG
 Compound Name N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 76 nM
External Link
CID: 10085818
TTD: D0A9MY
 Compound Name N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 195 nM
External Link
CID: 10265187
TTD: D0C9OT
 Compound Name PAULLONE Investigative [15]
Synonyms
142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 369401
TTD: D0D5ZL
 Compound Name 12,13-DEHYDRO-8-O-ACETYLMANZAMINE A Investigative [16]
Synonyms
CHEMBL252520
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4800 nM
External Link
CID: 23643836
TTD: D0E2XM
 Compound Name N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086782; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 661 nM
External Link
CID: 10085059
TTD: D0E6GC
 Compound Name 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine Investigative [9]
Synonyms
Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
CID: 10017019
TTD: D0F5EI
 Compound Name 9-N-METHYL-8-METHOXY-MANZAMINE A Investigative [16]
MOA Inhibitor
External Link
CID: 23643639
TTD: D0I3US
 Compound Name N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1086781; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 260 nM
External Link
CID: 9993220
TTD: D0IL0G
 Compound Name N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1097694; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 14000 nM
External Link
CID: 22319511
TTD: D0M3SC
 Compound Name 12,13-DEHYDROMANZAMINE A Investigative [16]
Synonyms
CHEMBL268202
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5400 nM
External Link
CID: 23643835
TTD: D0NL1F
 Compound Name CT-98024 Investigative [15]
Synonyms
556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.56 nM
External Link
CID: 9957049
TTD: D0Q3KS
 Compound Name N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide Investigative [26]
Synonyms
CHEMBL1085918; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5900 nM
External Link
CID: 10016510
TTD: D0R5EF
 Compound Name N-(6-chloro-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 354 nM
External Link
CID: 10421683
TTD: D0R6TL
 Compound Name 9-N-ETHYL-8-ETHOXY-MANZAMINE A Investigative [16]
Synonyms
CHEMBL403562
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10400 nM
External Link
CID: 23643537
TTD: D0R7QL
 Compound Name N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide Investigative [18]
MOA Inhibitor
Activity IC50 = 44 nM
External Link
CID: 135458003
TTD: D0S3RP
 Compound Name N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide Investigative [18]
Synonyms
CHEMBL1083208; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 935 nM
External Link
CID: 22319580
TTD: D0T1CE
 Compound Name CP-70949 Investigative [27]
Synonyms
PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0T8CQ
 Compound Name 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile Investigative [17]
Synonyms
CHEMBL1210236; BDBM50322829
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 26 nM
External Link
CID: 46894038
TTD: D0V6HG
 Compound Name DM-204 Investigative [27]
Synonyms
Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune
    Click to Show/Hide
External Link
TTD: D0WN1N
 Compound Name CHIR-98023 Investigative [9]
Synonyms
CT-98014
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.09 nM
External Link
CID: 9847557
TTD: D0X4CO
 Compound Name 8-O-(4-toluenesulfonyl)manzamine A Investigative [16]
Synonyms
CHEMBL403561
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 101437199
TTD: D0X4KR
 Compound Name N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide Investigative [26]
Synonyms
CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 80 nM
External Link
CID: 22319604
TTD: D0YM4A
 Compound Name CHIR-98014 Investigative [11]
Synonyms
CHIR98014; CHIR 98014
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.6 nM
External Link
CID: 53396311
TTD: D04ZWF
 Compound Name alsterpaullone 2-cyanoethyl Investigative [28]
Synonyms
alsterpaullone derivative7
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.8 nM
External Link
CID: 16760286
TTD: D05NKG
 Compound Name indirubin deriv. 8a Investigative [29]
MOA Inhibitor
External Link
CID: 135398521
TTD: D0B3ZB
 Compound Name LEUCETTAMINE B Investigative [30]
Synonyms
CHEMBL485053; SCHEMBL13219029
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10037501
TTD: D0K1DR
 Compound Name SB-415286 Investigative [9]
Synonyms
SB 415286; 264218-23-7; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 24 nM
External Link
CID: 4210951
TTD: D0N4WB
 Compound Name MANZAMINE A Investigative [31]
Synonyms
104196-68-1; CHEMBL611781; SCHEMBL11915472
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8400 nM
External Link
CID: 6509753
TTD: D0Q4QF
 Compound Name PYRAZOLOPYRIDAZINE 1 Investigative [32]
Synonyms
551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 10 nM
External Link
CID: 6539361
TTD: D02DLC
 Compound Name RGB-286147 Investigative [28]
Synonyms
pyrazolopyrimidone analog, RGB-286147
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 754 nM
External Link
CID: 135473382
TTD: D0J4ON
 Compound Name PYRAZOLOPYRIDAZINE 2 Investigative [32]
Synonyms
pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 10 nM
External Link
CID: 6539367
TTD: D0O0VP
 Compound Name K00244 Investigative [33]
Synonyms
GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 22 nM
External Link
CID: 6419766
TTD: D0Q7TO
DrugBank: DB08454
 Compound Name Quinoxaline1 Investigative [28]
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
CID: 438981
TTD: D0R5FH
 Compound Name TWS-119 Investigative [34]
Synonyms
TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 30 nM
External Link
CID: 9549289
TTD: D0T8KR
 Compound Name AS-601245 Investigative [35]
Synonyms
JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10109823
TTD: D04QCF
 Compound Name AZAKENPAULLONE Investigative [12]
Synonyms
1-Azakenpaullone; 676596-65-9; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, > AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18 nM
External Link
CID: 6538897
TTD: D0DR8N
 Compound Name Thieno analogue of kenpaullone Investigative [12]
Synonyms
Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 119.95 nM
External Link
CID: 6538761
TTD: D0TF9P
 Compound Name L-779450 Investigative [36]
Synonyms
303727-31-3; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9950176
TTD: D06WJA
 Compound Name NU-6102 Investigative [37]
Synonyms
nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4& -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 40 nM
External Link
CID: 4566
TTD: D0Y5RO
DrugBank: DB07126
 Compound Name PF-228 Investigative [38]
Synonyms
869288-64-2; PF-573228; PF 573228; PF573228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 1000 nM
External Link
CID: 11612883
TTD: D02QAZ
 Compound Name BX-912 Investigative [39]
Synonyms
BX 912; BX912
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11754511
TTD: D0IX7Y
 Compound Name BX-795 Investigative [39]
Synonyms
BX795; BX 795
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10077147
TTD: D0RG0Z
 Compound Name PMID19115845C89S Investigative [40]
Synonyms
3du8; GTPL8114; BDBM27380; DB07149
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 146 nM
External Link
CID: 16757525
TTD: D0T8NU
DrugBank: DB07149
 Compound Name STAUROSPORINONE Investigative [41]
MOA Inhibitor
External Link
TTD: D0GB4V
 Compound Name Ro31-8220 Investigative [41]
Synonyms
Bisindolylmaleimide IX; ro 31-8220; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl; bisindolymaleimide IX
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.8 nM
External Link
CID: 5083
TTD: D0M5FF
 Compound Name AMP-PNP Investigative [42]
Synonyms
Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 33113
TTD: D00ICA
 Compound Name ELLAGIC ACID Investigative [43]
Synonyms
476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7500 nM
External Link
CID: 5281855
TTD: D0A1CM
DrugBank: DB08846
 Compound Name CI-1040 Investigative [41]
MOA Inhibitor
External Link
CID: 6918454
TTD: D0B9BU
DrugBank: DB12429
 Compound Name 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole Investigative [44]
Synonyms
4,5,6,7-tetrabromobenzotriazole
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1694
TTD: D0O1YH
DrugBank: DB04462
 Compound Name 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative [45]
MOA Inhibitor
External Link
CID: 9859248
TTD: D0A5RM
 Compound Name Bisindolylmaleimide-I Investigative [41]
Synonyms
Bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 190.55 nM
External Link
CID: 2396
TTD: D0TO6S
DrugBank: DB03777
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [46]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [47]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [48]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [49]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [49]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [50]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [49]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [47]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [51]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [52]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [53]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [54]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [55]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [56]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [57]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [58]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [59]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [60]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [56]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [61]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [49]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [62]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [63]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [64]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [65]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3beta. Clin Transl Med. 2021 Oct;11(10):e602. doi: 10.1002/ctm2.602.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Evidence for irreversible inhibition of glycogen synthase kinase-3Beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904. doi: 10.1074/jbc.M111.306472. Epub 2011 Nov 18.
Ref 4 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977. doi: 10.1038/s41598-019-56461-4.
Ref 5 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin Ther Pat. 2017 Jun;27(6):657-666. doi: 10.1080/13543776.2017.1259412. Epub 2016 Nov 21.
Ref 6 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of Beta-catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874. doi: 10.1242/bio.030874.
Ref 7 Company report (Neurim Pharmaceuticals)
Ref 8 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3Beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6. doi: 10.1016/j.bmcl.2012.09.043. Epub 2012 Sep 23.
Ref 9 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. doi: 10.1016/j.ejmech.2008.08.012. Epub 2008 Sep 16.
Ref 10 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015;25(9):953-70. doi: 10.1517/13543776.2015.1045414. Epub 2015 Jul 13.
Ref 11 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. doi: 10.2337/diabetes.52.3.588.
Ref 12 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. doi: 10.1016/j.bmcl.2003.10.062.
Ref 13 AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem. 2013 May;125(3):446-56. doi: 10.1111/jnc.12203. Epub 2013 Mar 11.
Ref 14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796)
Ref 15 Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. doi: 10.1016/j.bmcl.2010.01.038. Epub 2010 Jan 25.
Ref 16 Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod. 2007 Sep;70(9):1397-405. doi: 10.1021/np060092r. Epub 2007 Aug 21.
Ref 17 Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93. doi: 10.1016/j.ejmech.2010.04.026. Epub 2010 Apr 28.
Ref 18 Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. doi: 10.1016/j.bmcl.2010.01.114. Epub 2010 Jan 25.
Ref 19 Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1525-8. doi: 10.1016/s0960-894x(02)00169-5.
Ref 20 Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem. 2008 Jan 15;16(2):636-43. doi: 10.1016/j.bmc.2007.10.047. Epub 2007 Oct 22.
Ref 21 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 22 Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem. 2004 Jun 15;12(12):3167-85. doi: 10.1016/j.bmc.2004.04.010.
Ref 23 Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod. 2006 Jul;69(7):1034-40. doi: 10.1021/np0601399.
Ref 24 Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95. doi: 10.1016/j.bmc.2010.07.045. Epub 2010 Jul 25.
Ref 25 Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. J Nat Prod. 2009 Dec;72(12):2199-202. doi: 10.1021/np9003905.
Ref 26 Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9. doi: 10.1016/j.bmcl.2010.01.132. Epub 2010 Feb 2.
Ref 27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
Ref 28 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. doi: 10.1073/pnas.0708800104. Epub 2007 Dec 11.
Ref 29 Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46. doi: 10.1021/jm031016d.
Ref 30 Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10. doi: 10.1016/j.ejmech.2009.10.009. Epub 2009 Oct 12.
Ref 31 2-N-Methyl modifications and SAR studies of manzamine A. Bioorg Med Chem. 2008 Jul 15;16(14):6702-6. doi: 10.1016/j.bmc.2008.05.079. Epub 2008 Jun 5.
Ref 32 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J Med Chem. 2004 Sep 9;47(19):4716-30. doi: 10.1021/jm040063i.
Ref 33 The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92. doi: 10.1016/j.bmcl.2009.04.136. Epub 2009 May 3.
Ref 34 Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. doi: 10.1038/nchembio0705-74.
Ref 35 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. doi: 10.1042/BJ20070797.
Ref 36 The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. doi: 10.1016/j.bmcl.2005.09.072. Epub 2005 Nov 2.
Ref 37 Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7. doi: 10.1016/j.bmcl.2005.11.048. Epub 2005 Dec 1.
Ref 38 Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. doi: 10.1074/jbc.M606695200. Epub 2007 Mar 28.
Ref 39 Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. doi: 10.1074/jbc.M501367200. Epub 2005 Mar 16.
Ref 40 First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. doi: 10.1021/jm800977q.
Ref 41 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. doi: 10.1042/0264-6021:3510095.
Ref 42 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 43 Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6. doi: 10.1021/jm060112m.
Ref 44 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. doi: 10.1021/jm049854a.
Ref 45 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 46 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 47 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 48 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 49 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 50 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 51 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 52 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 56 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 57 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 59 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 60 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 63 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 64 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 65 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.